RecallHawk

GENVOYA (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE)

GILEAD SCIENCES INC

Summary

FDA approved GENVOYA (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE) by GILEAD SCIENCES INC. NDA (New Drug) approval (Efficacy) on 2022-01-07. TABLET, ORAL.

Details

Source

Drug Approval

External ID

NDA207561-29

Action Date

2022-01-07

Status

Approved

Category

drug

Product Code

NDA (New Drug)

Product Description

GENVOYA (generic: ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE), TABLET, ORAL. Application: NDA207561

Context & Analysis

GILEAD SCIENCES INC has 11 FDA actions in our database, including 2 recalls.

Frequently Asked Questions

How often does GILEAD SCIENCES INC have FDA actions?

GILEAD SCIENCES INC has 11 FDA actions in our database, including 2 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "NDA207561-29" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions